BioSpace News Archive

BELLUS Health Inc. today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough (“RCC”).

Galecto, Inc. (NASDAQ: GLTO), a publicly listed company focused on the development of novel treatments for fibrosis and cancer, today announced that the first patient has been treated with the galectin-3 inhibitor GB1211 in the Phase 1b/2a GULLIVER-2 trial.

Walking Fish Therapeutics, a leader in B cell engineering, today announced the close of $50M Series A financing— led by investors including Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.

Anebulo Pharmaceuticals, Inc. today announced the completion of finished product manufacturing of its lead drug ANEB-001 for use in the Company’s upcoming Phase 2 clinical study.

Novamind Inc., a leading mental health company specialized in psychedelic medicine, is pleased to announce that its wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc., a clinical-stage neuroscience biopharmaceutical company.

UroGen (Nasdaq: URGN) today announced final data from two key trials, evaluating the safety and efficacy of investigational agent UGN-102

Cellworks Group, Inc. today announced that results from patient stratification studies will be featured in four poster presentations at the IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer and held virtually September 8-14, 2021.

Assure Holdings Corp. announced that management will participate in the Lake Street 5th Annual Best Ideas Growth (BIG5) Conference on Wednesday, September 15th, 2021.

SCYNEXIS, Inc. announced that Hansoh Pharmaceutical Group Company Limited has filed an investigational new drug application with the National Medical Products Administration of the People’s Republic of China for a Phase 3 study evaluating the efficacy and safety of ibrexafungerp for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the initiation of the first site for its pivotal ReMEDy2 Trial, a Phase 2/3 clinical study of DM199 for the treatment of acute ischemic stroke (AIS).